Oxford BioMedica plc Annual General Meeting

Oxford, UK – 03 June 2014: Oxford BioMedica (“the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

• Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and
• Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) on not less than 14 days’ notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company’s website at www.oxfordbiomedica.co.uk.
 
Certified copies of the document setting out the above resolutions passed at the 2014 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://www.morningstar.co.uk/uk/NSM.
 
The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (1 June 2014) there were 1,416,149,005 1p ordinary shares in issue, each carrying one vote per share.

-Ends-